Cargando…

A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation

Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Metelskaya, Victoria A., Gavrilova, Natalia E., Zhatkina, Maria V., Yarovaya, Elena B., Drapkina, Oxana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877383/
https://www.ncbi.nlm.nih.gov/pubmed/35207694
http://dx.doi.org/10.3390/jpm12020206
_version_ 1784658407841595392
author Metelskaya, Victoria A.
Gavrilova, Natalia E.
Zhatkina, Maria V.
Yarovaya, Elena B.
Drapkina, Oxana M.
author_facet Metelskaya, Victoria A.
Gavrilova, Natalia E.
Zhatkina, Maria V.
Yarovaya, Elena B.
Drapkina, Oxana M.
author_sort Metelskaya, Victoria A.
collection PubMed
description Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital for coronary angiography and ultrasound carotid dopplerography were enrolled into the study (n = 205 and n = 216, respectively). The extent of CA was assessed by Gensini Score (GS). Results: According to GS, participants were distributed as follows: atherosclerosis-free (GS = 0), CA of any stage (GS > 0), subclinical CA (GS < 35), severe CA (GS ≥ 35). Based on the analysis of mathematical models, including biochemical and imaging parameters, we selected and combined the most significant variables as i-BIO. The ability of i-BIO to detect the presence and severity of CA was estimated using ROC-analysis with cut-off points determination. Risk of any CA (GS > 0) at i-BIO > 4 was 7.3 times higher than in those with i-BIO ≤ 4; risk of severe CA (GS ≥ 35) at i-BIO ≥ 9 was 3.1 times higher than at i-BIO < 9. Results on the tested cohort confirmed these findings. Conclusions: The i-BIO > 4 detected CA (GS > 0) with sensitivity of 87.9%, i-BIO ≥ 9 excluded patients without severe CA (GS < 35), specificity 79.8%. Validation of i-BIO confirmed the feasibility of i-BIO > 4 to separate patients with any CA with sensitivity 76.2%, and of i-BIO ≥ 9 to exclude atherosclerosis-free subjects with specificity of 84.0%.
format Online
Article
Text
id pubmed-8877383
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88773832022-02-26 A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation Metelskaya, Victoria A. Gavrilova, Natalia E. Zhatkina, Maria V. Yarovaya, Elena B. Drapkina, Oxana M. J Pers Med Article Objective: To assess the feasibility of a combination of biochemical and imaging parameters for estimation of risk and severity of coronary atherosclerosis (CA), and to verify the created integrated biomarker (i-BIO) on independent cohort. Methods: Two cohorts of patients admitted to the hospital for coronary angiography and ultrasound carotid dopplerography were enrolled into the study (n = 205 and n = 216, respectively). The extent of CA was assessed by Gensini Score (GS). Results: According to GS, participants were distributed as follows: atherosclerosis-free (GS = 0), CA of any stage (GS > 0), subclinical CA (GS < 35), severe CA (GS ≥ 35). Based on the analysis of mathematical models, including biochemical and imaging parameters, we selected and combined the most significant variables as i-BIO. The ability of i-BIO to detect the presence and severity of CA was estimated using ROC-analysis with cut-off points determination. Risk of any CA (GS > 0) at i-BIO > 4 was 7.3 times higher than in those with i-BIO ≤ 4; risk of severe CA (GS ≥ 35) at i-BIO ≥ 9 was 3.1 times higher than at i-BIO < 9. Results on the tested cohort confirmed these findings. Conclusions: The i-BIO > 4 detected CA (GS > 0) with sensitivity of 87.9%, i-BIO ≥ 9 excluded patients without severe CA (GS < 35), specificity 79.8%. Validation of i-BIO confirmed the feasibility of i-BIO > 4 to separate patients with any CA with sensitivity 76.2%, and of i-BIO ≥ 9 to exclude atherosclerosis-free subjects with specificity of 84.0%. MDPI 2022-02-02 /pmc/articles/PMC8877383/ /pubmed/35207694 http://dx.doi.org/10.3390/jpm12020206 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Metelskaya, Victoria A.
Gavrilova, Natalia E.
Zhatkina, Maria V.
Yarovaya, Elena B.
Drapkina, Oxana M.
A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title_full A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title_fullStr A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title_full_unstemmed A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title_short A Novel Integrated Biomarker for Evaluation of Risk and Severity of Coronary Atherosclerosis, and Its Validation
title_sort novel integrated biomarker for evaluation of risk and severity of coronary atherosclerosis, and its validation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877383/
https://www.ncbi.nlm.nih.gov/pubmed/35207694
http://dx.doi.org/10.3390/jpm12020206
work_keys_str_mv AT metelskayavictoriaa anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT gavrilovanataliae anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT zhatkinamariav anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT yarovayaelenab anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT drapkinaoxanam anovelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT metelskayavictoriaa novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT gavrilovanataliae novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT zhatkinamariav novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT yarovayaelenab novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation
AT drapkinaoxanam novelintegratedbiomarkerforevaluationofriskandseverityofcoronaryatherosclerosisanditsvalidation